← Trials/Trial dossier/NCT00980785

SEAIRA

CompletedPhase 4Results posted

Studying the Effects of Antihypertensives on Individuals at Risk for Alzheimer's

Lead sponsor

University of Wisconsin, Madison

Asset

Ramipril

Listed sites

Recruiting sites

Enrollment

actual

Study population

Alzheimer’s disease

Key I/E criterion

•Age 40-65

Primary endpoint

•Cerebrospinal Fluid (CSF) Amyloid Beta-42 (Aβ42) Levels Between Baseline

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

Org study ID2014-1353

Secondary IDH-2009-0036UW Madison IRB

NCT IDNCT00980785

Secondary IDSMPH/MEDICINE/GER-AD DEVUW, Madison

Timeline

Milestones

Study start2009-04-09actual

Study first posted2009-09-21estimated

Primary completion2011-07-26actual

Study completion2011-07-26actual

Last update posted2020-08-25actual

Results first posted2020-08-25actual

Assets

Drug assets

Ramipril

Study populations

Who this study enrolls

Alzheimer’s disease

Eligibility

Who can enroll

Minimum age40 Years

Maximum age65 Years

SexAll

Healthy volunteersAccepted

Inclusion criteria

•Between the ages of 40 and 65

•Mean resting blood pressure between 130-160 systolic and 85-100 diastolic

•Parent with Alzheimer's Disease

Exclusion criteria

•Current involvement in another investigational drug trial.

•Potassium > 5.0

•Dementia based on DSMIV criteria

•Mini-Mental State Exam (MMSE) score < 27

•Current blood pressure medication (< 4 months from screening)

•Weight loss medication

•Contraindications for LP

•Know diagnosis or history of hospitalization due to congestive heart failure

•Elevated creatinine (females > 1.3 mg/dL or males > 1.4 mg/dL at baseline)

•Diabetes Type I and II

•Know adverse reaction to an ACE-I or an angiotensin receptor blocker

•Pregnant of nursing women

Endpoints (8)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other (unclassified)

Global cognition

Amyloid biomarkers

Global cognition

2 endpoints

Secondary/protocol endpoint

Change in CSF Angiotensin Converting Enzyme (ACE) Levels Between Baseline and Month 4 in Subjects Taking Ramipril vs Subjects on Placebo

Time frame:Baseline to 4 months

change from baseline, improvement

Secondary/registry result

Change in CSF Angiotensin Converting Enzyme (ACE) Levels Between Baseline and Month 4 in Subjects Taking Ramipril vs Subjects on Placebo

Time frame:Baseline to 4 months

change from baseline, improvement

Posted result

Group	Value (mean), U/L	Standard deviation
Placebon=6 Participants	-0.10	0.21
Activen=8 Participants	-0.63	0.32

Mean Difference (Final Values)-0.10p0.009Wilcoxon (Mann-Whitney)

Mean Difference (Final Values)-0.63p0.009Wilcoxon (Mann-Whitney)

Amyloid biomarkers

2 endpoints

Primary/protocol endpoint

Change in Cerebrospinal Fluid (CSF) Amyloid Beta-42 (Aβ42) Levels Between Baseline and Month 4 in Subjects Taking Ramipril vs Subjects on Placebo

Time frame:Baseline to 4 months

change from baseline, improvement

Primary/registry result

Change in Cerebrospinal Fluid (CSF) Amyloid Beta-42 (Aβ42) Levels Between Baseline and Month 4 in Subjects Taking Ramipril vs Subjects on Placebo

Time frame:Baseline to 4 months

change from baseline, improvement

Posted result

Group	Value (mean), pg/ml	Standard deviation
Placebon=6 Participants	-22.5	78.7
Activen=8 Participants	-31.71	90.6

Mean Difference (Final Values)-22.5p0.836Wilcoxon (Mann-Whitney)

Mean Difference (Final Values)-31.71p0.836Wilcoxon (Mann-Whitney)

Other (unclassified)

4 endpoints

Secondary/protocol endpoint/low confidence

Change in Flow-mediated Vasodilation (FMD) Between Baseline and Month 4 in Subjects Taking Ramipril vs Subjects on Placebo

Time frame:Baseline to 4 months

percent change from baseline, improvement

Secondary/protocol endpoint/low confidence

Change in Augmentation Index (%) Between Baseline and Month 4 in Subjects Taking Ramipril vs Subjects on Placebo

Time frame:Baseline to 4 months

change from baseline, improvement

Secondary/registry result/low confidence

Change in Flow-mediated Vasodilation (FMD) Between Baseline and Month 4 in Subjects Taking Ramipril vs Subjects on Placebo

Time frame:Baseline to 4 months

percent change from baseline, improvement

Posted result

Group	Value (mean), Percentage change	Standard deviation
Placebon=6 Participants	-0.70	1.56
Activen=8 Participants	-0.29	1.23

Mean Difference (Final Values)-0.70p0.755Wilcoxon (Mann-Whitney)

Mean Difference (Final Values)-0.29p0.755Wilcoxon (Mann-Whitney)

Secondary/registry result/low confidence

Change in Augmentation Index (%) Between Baseline and Month 4 in Subjects Taking Ramipril vs Subjects on Placebo

Time frame:Baseline to 4 months

change from baseline, improvement

Posted result

Group	Value (mean), Percentage change	Standard deviation
Placebon=6 Participants	1.7	8.9
Activen=8 Participants	-1.8	2.2

Mean Difference (Final Values)1.7p0.491Wilcoxon (Mann-Whitney)

Mean Difference (Final Values)-1.8p0.491Wilcoxon (Mann-Whitney)

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Wharton W, Stein JH, Korcarz C, Sachs J, Olson SR, Zetterberg H, Dowling M, Ye S, Gleason CE, Underbakke G, Jacobson LE, Johnson SC, Sager MA, Asthana S, Carlsson CM. The effects of ramipril in individuals at risk for Alzheimer's disease: results of a pilot clinical trial. J Alzheimers Dis. 2012;32(1):147-56. doi: 10.3233/JAD-2012-120763.
PMID22776970via BACKGROUND

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 21, 2026

Endpoint classificationDelfa ADRD endpoint taxonomy

Results tableClinicalTrials.gov results section

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.